A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Phase of Trial: Phase III
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms PIONEER6
- Sponsors Novo Nordisk
- 19 Jan 2017 Status changed from not yet recruiting to recruiting.
- 28 Oct 2016 Planned End Date changed from 1 Jun 2018 to 1 Oct 2018.
- 28 Oct 2016 Planned initiation date changed from 1 Oct 2016 to 1 Jan 2017.